Seaport Therapeutics

Company snapshot

Seaport Therapeutics is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. We have a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candi

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Seaport Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Seaport Therapeutics.

1. Jun 8, 2026 Clinical update

   SPT-300-2024-204 — Phase 2

2. Jun 5, 2026 Clinical update

   Placebo for SPT-300 — Phase 2

3. May 23, 2026 Clinical update

   SPT-300 — Phase 2

4. Dec 31, 2024 Patent grant

   Lymphatic system-directing lipid prodrugs

View all clinical trial activity →

• What is Seaport Therapeutics?

  Seaport Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker SPTX. Primary therapeutic focus areas include Major Depressive Disorder (MDD), with or without Anxious Distress, Major Depressive Disorder (MDD). NovaPharmaNews links 3 clin

• Is Seaport Therapeutics publicly traded?

  Yes. Seaport Therapeutics is listed with ticker SPTX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Seaport Therapeutics develop or market?

  We link 3 drug profile(s) where Seaport Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/seaport-therapeutics#company-drugs.

• What are the latest developments for Seaport Therapeutics?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Seaport Therapeutics focus on?

  Seaport Therapeutics focuses on Major Depressive Disorder (MDD), with or without Anxious Distress, Major Depressive Disorder (MDD) based on our analysis of their pipeline programs and drug development activities.